Absci (NASDAQ:ABSI – Get Free Report) released its earnings results on Tuesday. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.07), Zacks reports. The business had revenue of $0.65 million for the quarter, compared to the consensus estimate of $1.38 million. Absci had a negative return on equity of 61.95% and a negative net margin of 4,113.68%.
Here are the key takeaways from Absci’s conference call:
- ABS-201 has dosed the first three SAD cohorts in the phase I/IIa HEADLINE trial; management reports favorable emerging safety and PK data and is on track to dose SAD Cohort 4 and the first MAD cohort.
- Management laid out a near-term milestone timeline — primary safety/tolerability and PK data in H1 2026, a 13-week interim proof-of-concept in AGA in H2 2026, full 26-week POC in early 2027, and planned initiation of a phase II endometriosis trial in Q4 2026 (using HEADLINE safety/PK data).
- Company-backed market research and KOL feedback indicate strong patient interest in the ABS-201 target product profile (durable effect with ~2–3 subcutaneous doses over ~6 months); Absci estimates a U.S. AGA addressable population of ~15–18M and suggests the AGA TAM could exceed $25 billion annually if assumptions hold.
- Financials and strategy — Absci reported $144.3M in cash, cash equivalents, and marketable securities as of 12/31/25 (stated runway into H1 2028) and plans to prioritize ABS-201 while pursuing partnerships or transactions for other programs (ABS-101/301/501) to generate non-dilutive cash.
Absci Stock Performance
ABSI stock opened at $2.92 on Thursday. The company has a market capitalization of $439.08 million, a P/E ratio of -3.44 and a beta of 2.12. The company has a fifty day moving average price of $2.77 and a 200-day moving average price of $3.21. Absci has a 52-week low of $2.01 and a 52-week high of $5.23.
Analysts Set New Price Targets
View Our Latest Stock Report on Absci
Absci News Summary
Here are the key news stories impacting Absci this week:
- Positive Sentiment: Early ABS-201 clinical progress — Absci reported dosing the first three SAD cohorts in the ABS-201 HEADLINE trial with favorable emerging safety data, a tangible pipeline milestone that supports longer-term value upside. Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
- Positive Sentiment: Analyst support — Needham & Company reaffirmed a Buy rating and set a $7.00 price target, implying substantial upside from current levels and providing a counterbalance to recent weak results. Needham buy rating reaffirmed (Benzinga)
- Neutral Sentiment: Full earnings call transcript and highlights are available — management framed Q4 and FY2025 results alongside strategic updates; investors should read the call for detail on cash runway, partnering plans, and program timelines. Absci Q4 2025 Earnings Call Transcript (Seeking Alpha)
- Neutral Sentiment: Pre-market coverage noted broader weakness — Absci appeared among names moving lower in pre-market commentary, reflecting market reaction to the combined earnings and pipeline headlines rather than a single clear driver. Absci, DigitalOcean and other big stocks moving lower in Wednesday’s pre-market session
- Neutral Sentiment: Short-interest data published in recent feeds looks unreliable/zeroed (reports show 0 shares and NaN changes); treat those numbers cautiously until exchanges/administrators reconcile them. (No reliable article link available.)
- Negative Sentiment: Quarterly miss — Absci reported Q4 EPS of ($0.23) versus consensus ($0.16) and revenue of $0.65M vs. $1.38M expected, a miss that reduces near-term fundamental support and likely fueled selling pressure. Absci Corporation (ABSI) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
- Negative Sentiment: Analyst downgrade citing pipeline pivot — A Seeking Alpha note downgraded Absci to Hold after management appears to de-emphasize ABS-101 in favor of ABS-201, a shift that could delay or reduce near-term value capture from earlier programs and compress the stock’s valuation. Absci: Downgrade To ‘Hold’ As ABS-101 On Back Burner And Pivot To ABS-201
Insider Transactions at Absci
In related news, insider Andreas Busch acquired 100,000 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The shares were bought at an average cost of $2.29 per share, with a total value of $229,000.00. Following the completion of the purchase, the insider directly owned 421,446 shares in the company, valued at $965,111.34. The trade was a 31.11% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Sean Mcclain sold 26,761 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $2.99, for a total value of $80,015.39. Following the completion of the sale, the chief executive officer owned 8,334,567 shares in the company, valued at $24,920,355.33. The trade was a 0.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 10.49% of the company’s stock.
Institutional Investors Weigh In On Absci
Large investors have recently bought and sold shares of the stock. Invesco Ltd. increased its stake in Absci by 14.3% in the fourth quarter. Invesco Ltd. now owns 54,550 shares of the company’s stock valued at $190,000 after purchasing an additional 6,826 shares in the last quarter. XTX Topco Ltd boosted its position in shares of Absci by 380.9% during the 4th quarter. XTX Topco Ltd now owns 136,874 shares of the company’s stock worth $478,000 after purchasing an additional 108,413 shares in the last quarter. Wellington Management Group LLP increased its position in Absci by 8.5% in the 4th quarter. Wellington Management Group LLP now owns 410,124 shares of the company’s stock valued at $1,431,000 after buying an additional 32,267 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in Absci during the 4th quarter worth approximately $8,201,000. Finally, Abel Hall LLC acquired a new position in Absci during the 4th quarter worth approximately $54,000. 52.05% of the stock is currently owned by institutional investors and hedge funds.
About Absci
Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.
The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.
Further Reading
Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.
